Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Goldman Sachs has raised its price target on Livanova (NASDAQ:LIVN) to $168.00 from $162.00 while maintaining a Buy rating following the company’s second-quarter 2025 results. Currently trading at $48.52, the stock has shown strong momentum with an 18% gain over the past week. According to InvestingPro data, analysts maintain a bullish consensus with price targets ranging from $55 to $80.
The investment bank cited better-than-expected performance in Livanova’s Concerts segment and approximately in-line results in Sponsorships & Ticketing. Livanova exceeded expectations across multiple metrics, including Fan Count (44.2 million versus 42.9 million), fee-bearing ticket sales (83.3 million versus 80.8 million), total revenue ($7.01 billion versus $6.78 billion) and AOI ($798 million versus $756 million).
These strong results came despite the negative impact of the canceled Bonnaroo festival, Goldman Sachs noted. The company also provided updated forward-looking commentary on underlying supply and demand trends for 2025 and 2026.
Goldman Sachs believes these trends support potential upside to consensus expectations for 2025 AOI growth. The firm projects 16.3% year-over-year growth to $2,500 million, approximately 3% above pre-earnings consensus. InvestingPro analysis suggests the stock is currently undervalued, with 5 analysts recently revising their earnings estimates upward. Subscribers can access 7 additional exclusive ProTips and comprehensive valuation metrics for LIVN.
The investment bank has increased its outlook for 2025 and beyond AOI by approximately 1% to reflect the second-quarter beat, driven by strong underlying performance in the core Concerts segment, slightly offset by weaker than expected second-half trends in Ticketing due to an international mix shift where take rates are lower than domestic.
In other recent news, LivaNova reported second-quarter results that exceeded analyst expectations, showcasing robust performance across its business segments. The company achieved adjusted earnings per share of $1.05, surpassing the consensus estimate of $0.87. Revenue for the quarter reached $352.5 million, which was above the anticipated $332.21 million, marking a 10.7% increase compared to the previous year. On an organic basis, revenue grew by 10.3%. Following this strong quarterly performance, Mizuho (NYSE:MFG) raised its price target for LivaNova to $65 from $55, maintaining an Outperform rating. The revenue beat by $20 million and earnings exceeding expectations by $0.18 per share were highlighted as key factors. Mizuho attributed the company’s success to continued momentum in its Cardiopulmonary segment, particularly due to the Essenz HLM launch across Europe. These developments reflect LivaNova’s upward trajectory and positive reception in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.